SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is experiencing heightened volatility as the market reacts to conflicting signals regarding the Iran-U.S. conflict, including reports of potential troop deployments and fluctuating oil prices. The community is actively debating whether recurring administration announcements are genuine de-escalation efforts or market-manipulation tactics, leading to increased skepticism among traders regarding price stability.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is currently trending as the stock faces significant downward pressure following legal rulings in California and New Mexico that found the company liable for addictive product design and failure to protect younger users. The community is deeply divided between long-term investors viewing the dip as a prime buying opportunity for a cash-generating leader, and bears who are concerned that these legal precedents and ongoing AI infrastructure spending could lead to a sustained downward trend.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending as investors react to the company's high-volatility trading and political speculation surrounding the latest military and geopolitical developments in the Middle East. Community discussion remains polarized, with users actively debating the stock's financial fundamentals, market manipulation claims, and the broader economic impact of the ongoing conflict.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is trending as investors weigh conflicting reports regarding potential ceasefire negotiations and persistent geopolitical tensions in the Middle East. Community discussions are heavily focused on the impact of potential Strait of Hormuz disruptions and ongoing volatility driven by high-stakes diplomatic rhetoric.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is trending as investors weigh significant long-term growth prospects, supported by major hyperscaler contracts and positive analyst coverage, against immediate market volatility driven by geopolitical tensions. The community is actively discussing the stock's resilience, with many retail traders viewing recent pullbacks as a strategic opportunity to accumulate shares ahead of expected future data center capacity expansions.

Pelican Acquisition Corp. is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded on July 23, 2024 and is headquartered in New York, NY.

Greenland Energy Co.

Greenland Energy Co. is attracting significant investor attention following the finalization of its business combination and the appointment of former TD Ameritrade CEO Joe Moglia as an executive advisor. The community is actively debating the company's long-term potential, focusing on its ambitious Jameson Land Basin drilling project and the strategic implications of its Arctic oil exploration.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology (MU) is seeing intense volatility as investors weigh record-breaking financial results and strong AI-driven memory demand against broader geopolitical tensions and market concerns over the long-term impact of Google's TurboQuant efficiency research. The community is sharply divided, with bulls highlighting the stock's low forward P/E and sold-out HBM capacity as a generational buying opportunity, while bears and short-sellers are actively betting on further downside amidst a multi-day sell-off.

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.

Kodiak Sciences Inc

Kodiak Sciences is trending as shares surged following positive topline Phase 3 results for its drug candidate Zenkuda, which met primary and secondary endpoints in treating diabetic retinopathy. The community is actively debating the stock's potential for a short squeeze given the high short interest, while supporters emphasize this as a fundamental re-rating of the company's platform and pipeline execution rather than mere speculative hype.

Crane Harbor Acquisition Corp. operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded on January 2, 2025 and is headquartered in Philadelphia, PA.

Crane Harbor Acquisition Corp. - Ordinary Shares - Class A

Crane Harbor Acquisition Corp.

Crane Harbor Acquisition Corp. is trending as it finalizes its business combination with Xanadu Quantum Technologies, set to transition to the ticker $XNDU. The community is focused on the potential for a short squeeze due to high redemption rates creating a micro-float and significant short interest, while tracking the company's strategic quantum hardware roadmap and new government support.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is under intense scrutiny as shareholders debate the impact of the upcoming TDAPA reimbursement transition, leading to significant volatility despite recent buyback authorizations and positive institutional interest. The community is actively tracking potential legislative catalysts like the Kidney Care Access Protection Act and awaiting Phase III results for Rezzayo as key factors to resolve the company's current valuation gap.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Is Jazz (JAZZ) Down 3.9% Since Last Earnings Report?

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

MassMutual Private Wealth & Trust FSB Sells 7,073 Shares of Jazz Pharmaceuticals PLC $JAZZ

MassMutual Private Wealth & Trust FSB lowered its position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 95.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 353 shares of the specialty pha...

American Nutrition Association Announces Initiative with Jazz Pharmaceuticals to Advance Evidence-Based Sodium Reduction and Cardiovascular Health Education

American Nutrition Association Announces Initiative with Jazz Pharmaceuticals to Advance Evidence-Based Sodium Reduction and Cardiovascular Health Education American Nutrition Association Announces...

Groupama Asset Managment Lowers Position in Jazz Pharmaceuticals PLC $JAZZ

Groupama Asset Managment decreased its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 70.5% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,576 shares of the specialty pharmaceutical company's stock after selling 6,142 s...

Jazz Pharmaceuticals (NASDAQ:JAZZ) Given New $232.00 Price Target at Piper Sandler

Piper Sandler lifted their target price on Jazz Pharmaceuticals from $219.00 to $232.00 and gave the stock an "overweight" rating in a report on Thursday...

Goldentree Asset Management LP Takes $149.60 Million Position in Jazz Pharmaceuticals PLC $JAZZ

Goldentree Asset Management LP purchased a new stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the...

Jazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026

Jazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026 Jazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing...

Faithward Advisors LLC Increases Position in Jazz Pharmaceuticals PLC $JAZZ

Faithward Advisors LLC raised its holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 93.4% in the third quarter, according to the company in its most recent filing with the...

Holocene Advisors LP Acquires 135,367 Shares of Jazz Pharmaceuticals PLC $JAZZ

Holocene Advisors LP raised its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 28.8% in the third quarter, according to the company in its most recent Form 13F filing...

Ameriprise Financial Inc. Cuts Stock Holdings in Jazz Pharmaceuticals PLC $JAZZ

Ameriprise Financial Inc. trimmed its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 1.1% during the 3rd quarter, according to the company in its most recent disclosure with the...

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Jazz Pharmaceuticals plc

Alphabet $GOOGL

Robinhood $HOOD

Rocket Lab $RKLB

Sandisk $SNDK

The ticker that owned the conversation. This award honors the stock that defined the market narrative through engagement, price action, and cultural presence on the boards.

Current Price	$189.15
Prev Close	$189.08
Open	$187.16
Dividend Yield	0.00%
50-Day Moving Average	$175.49
Beta	0.71
Avg. Volume	1.09M
PE Ratio	-31.68

52-Week High	$198.00
52-Week Low	$95.49
Market Capitalization	$11.64B
EPS (Annual)	-$5.84
Price to Book	2.69
Revenue Per Employee	$1.48M

JAZZ
Jazz Pharmaceuticals plc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest JAZZ News

JAZZJazz Pharmaceuticals plc